doxorubicin hydrochloride,brentuximab,dacarbazine,filgrastim,pegfilgrastim,nivolumab,vinblastine sulfate
seagen,amgen,bms
['s1826']
n-avd improved pfs vs bv-avd in pts with as hl few immune aes were observed and &lt; 1% of pts received rt longer follow-up is needed to assess os and pros s1826, the largest hl study in nctn history, is a key step towards harmonizing pediatric &amp; adult treatment of as hl #asco23 
Director Pediatric Hematology Oncology & Bone Marrow Transplant, Medanta The Medicity . RT are not endorsement and views are my own